BackReata Pharmaceuticals Overview

Reata Pharmaceuticals Accounts Payable

Track Reata Pharmaceuticals's accounts payable ($20M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$19.86M
↑ 156.13% YoYΔ $12.11M vs prior year quarter

Peer average

Loading

Reata Pharmaceuticals Accounts Payable History

Loading

Reata Pharmaceuticals vs. peers: Accounts Payable Comparison

Loading

Reata Pharmaceuticals Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Reata Pharmaceuticals (RETA) FAQ

As of the most recent data (June 2023), RETA shows a accounts payable of $20M. That compares with $7.8M in the prior-year period — up 156.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RETA's accounts payable is now $20M (was $7.8M) — a 156.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Reata Pharmaceuticals is outperforming or lagging.

Tracking RETA's accounts payable over time shows whether Reata Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $20M That compares with $7.8M in the prior-year period — up 156.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Reata Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $20M) with ownership activity and broader fundamentals.

Reata Pharmaceuticals's accounts payable is $20M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.